Based in Sweden, Empros Pharma is a startup. Brouky records 1 investor associated with the company.
Empros Pharma is developing EMP16, an oral weight-loss maintenance pharmaceutical that combines orlistat and acarbose in a controlled-release formulation to block fat and carbohydrate absorption locally in the gut. The company is pursuing clinical development (Phase 2b data reported) with the aim of a first-line, safe oral treatment for obesity.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.